Tissue Diagnostics Market Is Likely To Up Demand At A USD 8.99 Billion By 2030

 San Francisco, 28 Dec 2023: The Report Tissue Diagnostics Market Size, Share & Trends Analysis Report By Technology (ISH, Digital Pathology), By Application (Breast Cancer, Prostate Cancer), By End-use, By Region, And Segment Forecasts, 2023 - 2030

The global tissue diagnostics market size is expected to reach USD 8.99 billion by 2030, growing at 7.15% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. Accelerating demand for automated tissue diagnostic systems due to a lack of skilled pathologists has driven the tissue diagnostics industry. The advent of advanced imaging techniques, such as auto fluorescence, that minimize the need for invasive diagnostics further supplements the market growth.

The use of digital slides has significantly increased in recent years, owing to its associated benefits including flexible magnification and remote access to slides. The growing emphasis on precision medicine is supported by several organizations & companies in the U.S., which is expected to contribute to the market growth. Additionally, companies are supporting the development of precision medicine with novel oncology solutions. For instance, in May 2020, QIAGEN launched new oncology solutions, such as the QCI Interpret One software solution for genomic profiling of tumors. The advancements in imaging techniques are expected to positively influence market growth.

In addition, one of the emerging trends in the tissue diagnostics industry is the integration of digital pathology and artificial intelligence (AI). Digital pathology involves the scanning and digitization of tissue slides, allowing pathologists to review and analyze images remotely. AI algorithms can then be applied to these digital images to aid in the interpretation and analysis of tissue samples. This integration enables faster and more accurate diagnoses, enhances workflow efficiency, and improves patient care. It also facilitates the development of predictive models and precision medicine approaches. As a result, there is a growing demand for digital pathology solutions and AI-driven tissue diagnostics platforms in the market.

With technological improvements in imaging techniques, the sensitivity of detection and diagnosis of breast cancer has also improved. For instance, in May 2023, with an emphasis on AI-guided breast cancer diagnoses, BPGbio recently announced an agreement with the Department of Defense (DoD). The new panel, created with artificial intelligence, is intended to detect women diagnosed with ER+ breast cancer but do not react to hormone therapy, allowing for more suitable treatment alternatives and improving treatment response.

The unique 34-gene breast cancer diagnostic panel from BPGbio will also receive wider evaluation through the Interrogative Biology Platform, focusing on ER+ breast cancers, which are significantly rising. Technological expansion in breast tissue analysis includes procedures for evaluating gene expression, cellular biochemistry, and molecular biology using digital methods, tomosynthesis, CAD, and other methods.

Access Research Report of Tissue Diagnostics Market @ https://www.grandviewresearch.com/industry-analysis/tissue-diagnostics-market

Tissue Diagnostics Market Report Highlights

• The IHC segment held the largest share of the tissue diagnostics industry in 2022. IHC tests are highly adopted as these tests provide precision and help identify the variations between different types of cancer, resulting in the largest revenue share
• The digital pathology and workflow segment is expected to grow at the fastest CAGR during the study period. A rise in investments in the development of advanced infrastructure to digitalize images is anticipated to drive the digital pathology segment. Moreover, an increase in the demand for automated modalities owing to a dearth of skilled pathologists further compliments this growth
• A large number of breast cancer cases coupled with a rise in the application of digital image processing techniques on histopathological samples for breast cancer detection contributes to the largest share of the tissue diagnostics industry
• The hospital segment dominated the tissue diagnostics industry in 2022 due to the high adoption of tissue diagnostics solutions. These solutions provide more accurate results in minimal time than conventional testing procedures
• North America accounted for the largest revenue share of the tissue diagnostics industry in 2022 owing to increasing collaborations between pharmaceutical and biotech firms to expand their product offerings
• Abbott, QIAGEN, Roche, Siemens, Danaher, Thermo Fisher, and Merck are some key participants operating in the market. Key vendors are engaged in novel product developments, partnerships, and acquisition models to maintain their revenue share in the market

Tissue Diagnostic Market Report Scope

Report Attribute	Details
Market size value in 2023	USD 5.55 billion
Revenue forecast in 2030	USD 8.99 billion
Growth rate	CAGR of 7.15% from 2023 to 2030
Base year for estimation	2023
Historical data	2018 - 2021
Forecast period	2023 - 2030

List of Key Players in the Tissue Diagnostics Market

• Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Siemens
• Danaher
• bioMérieux SA
• QIAGEN
• BD
• Merck KGaA
• GE Healthcare
• BioGenex
• Cell Signaling Technology, Inc.
• Bio SB
• DiaGenic ASA
• Agilent Technologies

Access Press Release of Tissue Diagnostics Market @ https://www.grandviewresearch.com/press-release/global-tissue-diagnostic-market